Achieve Life Sciences (NASDAQ:ACHV) Stock Crosses Above 200 Day Moving Average - Should You Sell?

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report)'s stock price crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $3.19 and traded as high as $4.29. Achieve Life Sciences shares last traded at $3.83, with a volume of 640,184 shares traded.

Achieve Life Sciences Price Performance

The stock has a market capitalization of $132.84 million, a P/E ratio of -3.39 and a beta of 1.63. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.78 and a current ratio of 6.78. The stock has a 50-day simple moving average of $2.67 and a 200 day simple moving average of $3.16.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last posted its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). On average, equities analysts forecast that Achieve Life Sciences, Inc. will post -1.17 earnings per share for the current fiscal year.

Insider Buying and Selling at Achieve Life Sciences

In other Achieve Life Sciences news, CFO Mark K. Oki bought 10,000 shares of Achieve Life Sciences stock in a transaction dated Monday, March 17th. The stock was bought at an average cost of $2.89 per share, for a total transaction of $28,900.00. Following the purchase, the chief financial officer now owns 10,000 shares of the company's stock, valued at $28,900. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 3.00% of the company's stock.

Institutional Trading of Achieve Life Sciences

Several institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC boosted its stake in Achieve Life Sciences by 185.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,545 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 4,905 shares during the period. Wells Fargo & Company MN boosted its stake in Achieve Life Sciences by 7.2% in the 4th quarter. Wells Fargo & Company MN now owns 74,933 shares of the biopharmaceutical company's stock valued at $264,000 after purchasing an additional 5,059 shares during the period. LPL Financial LLC boosted its stake in Achieve Life Sciences by 2.9% in the 4th quarter. LPL Financial LLC now owns 196,833 shares of the biopharmaceutical company's stock valued at $693,000 after purchasing an additional 5,500 shares during the period. Barclays PLC boosted its stake in Achieve Life Sciences by 12.2% in the 4th quarter. Barclays PLC now owns 53,473 shares of the biopharmaceutical company's stock valued at $189,000 after purchasing an additional 5,818 shares during the period. Finally, Geode Capital Management LLC boosted its stake in Achieve Life Sciences by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 755,845 shares of the biopharmaceutical company's stock valued at $2,661,000 after purchasing an additional 6,736 shares during the period. 33.52% of the stock is currently owned by institutional investors.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.